Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medi-Weightloss vs REMEVi

Medi-Weightloss
Graded #126

Lower grade

vs+0.8000000000000114
REMEVi
Graded #108

Higher grade

The verdict

REMEVi takes it — 70.4/100 to 69.6/100, but only just.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated. Medi-Weightloss is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
54
54
Dose & formulationMedi-Weightloss +1
65
64
Clinical oversightMedi-Weightloss +1
87
86
Labs & monitoringMedi-Weightloss +25
90
65
FulfillmentREMEVi +32
65
97
Contract termsREMEVi +14
55
69
Medi-Weightloss · left barREMEVi · right bar

The numbers

MetricMedi-WeightlossREMEVi
WeighScore69.6/10070.4/100
GradeCC
Scorecard rank#126#108
Semaglutide$199/mo (promotional rate, brand-name)$199/mo (starting dose, compounded)
TirzepatideNot disclosed$269/mo (starting dose, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Medi-Weightloss

Graded #126 · C

Strengths

  • Both branded (Wegovy, Zepbound) and compounded semaglutide/tirzepatide
  • Established brand with 130+ physician-supervised locations nationwide
  • Telehealth plus in-person clinic options
  • Accepts insurance at many locations; HSA/FSA welcome
  • Includes body-composition analysis and personalized plans

Where it loses points

  • Ongoing medication pricing not transparently posted; varies by plan
  • $199 new-patient visit fee before medication costs
  • Frequent (often weekly) visits expected for some patients
  • Compounded products are not FDA-approved or evaluated
REMEVi

Graded #108 · C

Strengths

  • The first bilingual GLP-1 clinic — care delivered in English and Spanish by clinicians trained in both, not auto-translated
  • Compounded semaglutide from $199/mo and tirzepatide from $269/mo on the 52-week plan, with the same price every month (no titration price hikes)
  • LegitScript-certified and licensed in all 50 states + DC, with an NPI-verified pharmacy and overnight shipping
  • Transparent all-inclusive pricing with no hidden fees and cancel anytime; full legal suite (Privacy, Terms, HIPAA, Refund)

Where it loses points

  • Lowest pricing requires a 52-week commitment — month-to-month is higher ($279 semaglutide / $339 tirzepatide)
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy or Zepbound
  • The specific compounding pharmacy is not named (described as 'NPI-verified')
  • A newer, patient-founded clinic; press mentions (Fortune, AP, Reuters) are syndicated PR, not editorial endorsements

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard